This is the authors' abstract. We don't add key points for this paper.
Xanthohomul (XN), a naturally prenylated flavonoid, is extracted from hops (Humulus lupulus L.; Cannabaceae). XN treated NG108-15 cells significantly decreased cell viability through increased ROS and arrested the cell cycle at G1/S phase. Notably, XN treatment did not induce apoptotic responses. Further research revealed XN-treatment increased reactive oxygen species (ROS) levels which was alleviated by N-acetyl-L-cysteine (NAC). Moreover, XN triggered the phosphorylation of the estrogen-regulated kinase (ERK1/2) and p38 mitogen activated protein kinase (MAPK). Intriguingly, our observations indicated that only ERK inhibitor could partly relieve XN-induced G1/S cycle arrest and proliferation inhibition. Hence, XN emerges as a prospective candidate for an anti-neurotumor pharmaceutical agent.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: